Question: What are the new class of cancer drugs called, which avoid the side effects of cytotoxics.
About the article "Chemotherapy", section "Cytotoxics and targeted therapies".

Candidate passages:
Targeted therapies are a relatively new class of cancer drugs that can overcome many of the issues seen with the use of cytotoxics.
They are divided into two groups: small molecule and antibodies.
The massive toxicity seen with the use of cytotoxics is due to the lack of cell specificity of the drugs.
They will kill any rapidly dividing cell, tumor or normal.
Targeted therapies are designed to affect cellular proteins or processes that are utilised by the cancer cells.
This allows a high dose to cancer tissues with a relatively low dose to other tissues.
As different proteins are utilised by different cancer types, the targeted therapy drugs are used on a cancer type specific, or even on a patient specific basis.
Although the side effects are often less severe than that seen of cytotoxic chemotherapeutics, life-threatening effects can occur.
Initially, the targeted therapeutics were supposed to be solely selective for one protein.
Now it is clear that there is often a range of protein targets that the drug can bind.
An example target for targeted therapy is the protein produced by the Philadelphia chromosome, a genetic lesion found commonly in chronic myelomonocytic leukemia.
This fusion protein has enzyme activity that can be inhibited by imatinib, a small molecule drug.
Pharmacogenomics has applications in illnesses like cancer, cardiovascular disorders, depression, bipolar disorder, attention deficit disorders, HIV, tuberculosis, asthma, and diabetes.
In cancer treatment, pharmacogenomics tests are used to identify which patients are most likely to respond to certain cancer drugs.
In behavioral health, pharmacogenomic tests provide tools for physicians and care givers to better manage medication selection and side effect amelioration.
Pharmacogenomics is also known as companion diagnostics, meaning tests being bundled with drugs.
Examples include KRAS test with cetuximab and EGFR test with gefitinib.
Beside efficacy, germline pharmacogenetics can help to identify patients likely to undergo severe toxicities when given cytotoxics showing impaired detoxification in relation with genetic polymorphism, such as canonical 5-FU.
In cardio vascular disorders, the main concern is response to drugs including warfarin, clopidogrel, beta blockers, and statins.
There are currently over 120 U.S. Food and Drug Administration approved drugs that include pharmacogenomic biomarkers in their labels. 
Because of numerous adverse effect and limitations in use, new drugs with better properties are needed.
Especially are desired improvements in antitumor activity, toxicity profile, drug formulation and pharmacology.
Currently have been suggested few approaches in development of novel therapeutic agents with better properties   Discovery agents which are not a substrate for efflux pump or modifications of drugs in toward lower affinity to transporting proteins.
Discover P-glycoprotein inhibitors with higher affinity to the transporter then drugs, is next approach.
For improving oral bioavailability is suggested co-administration of P-gp and cytochrome inhibitors with anticancer drugs.
Development of inhibitors that have their binding site in α-tubulin.
This part of tubulin dimer remains unused because all currently use drugs bind to the β-tubulin.
Research in this field can open new opportunity in treatment and provide new class of inhibitors.
One of the targets for anticancer drugs can be tumor vasculature.
The advantage in this case is relatively easy access of therapeutic agents to the target.
It is known that some compounds can inhibit the formation of new blood vessels (inhibit the process of angiogenesis) or shut down existing ones.
Tumor cells die very fast after cutting off the oxygen supply what suggest these agents are especially interesting.
What more, it seems the agents act only with tumor vasculature and do not interact with normal tissues.
The mechanisms is not known but has been suggested that the reason are differences between young tissue of tumor and mature tissue of normal vasculature.
Antivascular agents are similar to colchicine and bind to the colchicine binding site on β-tubulin so development of novel agents acting with colchicine binding site (which is not used by any of currently approved drugs) seems to be a promising approach.
Therapy with combination of two or more drugs which have various binding sites and/or different mechanism of action but have non overlapping adverse effects.
This would allow use of drugs in low concentration what reduce strength of side effects associated with high doses of anticancer agents.
Better efficiency might be also a result of maintenance low concentrations of drugs for long period instead of drastic changes in the amount of administered drugs.
Liposomes and polymer-bound drugs comprise promising improvements in delivery system.
Liposomes allow for delivery considerable amounts of drag to the tumor without toxic effect in normal tissues and slowly release drugs what result in prolongation of pharmaceutical action.
Similar properties have drugs bound to polymer.
In addition use of water soluble polymers allow hydrophilic anticancer agents become soluble.
The nature of polymer-drug linkage can be designed to be stable in normal tissues and break down in tumor environment, which is more acidic.
This approach allow for release active agent exactly in the target.
Discover new compounds active against drug-resistant cancers with different mechanism than drugs have been already known.
Elucidation of all resistance mechanisms and design drugs which avoid it.  
In the treatment of cancer, chemoprotective agents are drugs which protect healthy tissue from the toxic effects of anticancer drugs.  
Treosulfan is a substance that is being studied in the treatment of cancer.
It belongs to the family of drugs called alkylating agents.
Its has been used mainly as a substitute of busulfan in frail patients, as the side effects and toxicity are supposedly less severe.